+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class, Route of Administration, and Distribution Channel

  • ID: 5359792
  • Report
  • May 2021
  • Region: Europe
  • 143 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Horizon Therapeutics plc
  • Merck & Co., Inc.
  • Novartis AG
The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.



According to this study, the Europe multiple sclerosis therapeutics market is expected to reach US$ 13,281.11 million by 2027 from US$ 8,423.83 million in 2019; it is estimated to grow with a CAGR of 6.0% from 2020 to 2027. The report highlights trends prevailing in the Europe multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.

The Europe multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.

In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of multiple sclerosis disease and help the patients in making educated decisions regarding its treatment. Also, the National MS Society created and launched the “MS Kills Connection > The report segments in Europe Multiple Sclerosis Therapeutics Market as follows:

By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
By Country
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Horizon Therapeutics plc
  • Merck & Co., Inc.
  • Novartis AG
1. Introduction
1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 Europe Multiple Sclerosis Therapeutics Market - By Route Of Administration
1.3.3 Europe Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 Europe Multiple Sclerosis Therapeutics Market - By Country

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe - PEST Analysis
4.3 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - Europe Analysis
6.1 Europe Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 - Europe Analysis
10.1 Europe: Multiple Sclerosis Therapeutics Market
10.1.1 Overview
10.1.2 Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
10.1.3 Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.1 Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.3.2 Germany Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.3.3 Germany Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.3.4 Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.4 UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.1 UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.2 UK Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.4.3 UK Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.4.4 UK Multiple Sclerosis Therapeutics Market, by Distribution Channel- Revenue and Forecast to 2027 (USD Million)
10.1.5 France: Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.1 France: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.2 France Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.5.3 France Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.5.4 France Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.6 Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.6.1 Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.6.2 Spain Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.6.3 Spain Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.6.4 Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.7 Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Italy Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Italy Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.8 Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.8.3 Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
10.1.8.4 Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)

11. Impact of COVID-19 Pandemic on Europe Multiple Sclerosis Therapeutics Market
11.1 Europe: Impact Assessment Of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. Germany Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 2. Germany Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 3. Germany Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 4. UK Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 5. UK Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 6. UK: Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million).
Table 7. France Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 8. France Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 9. France Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 10. Spain Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 11. Spain Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 12. Spain Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 13. Italy Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 14. Italy Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 15. Italy Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 16. Rest of Europe Multiple Sclerosis Therapeutics Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
Table 17. Rest of Europe Multiple Sclerosis Therapeutics Market, by Route of Administration - Revenue and Forecast to 2027 (USD Million)
Table 18. Rest of Europe Multiple Sclerosis Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
Table 19. Organic Developments Done By Companies
Table 20. Inorganic Developments Done by Companies
Table 21. Glossary of Terms, Multiple sclerosis therapeutics Market

List of Figures
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Multiple Sclerosis Therapeutics Market
Figure 5. Europe Multiple Sclerosis Therapeutics Market - Leading Country Markets (US$ Million)
Figure 6. Europe PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Europe Multiple Sclerosis Therapeutics Market - Revenue Forecast and Analysis - 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 19. Europe: Multiple Sclerosis Therapeutics Market, by Key Country - Revenue (2019) (USD Million)
Figure 20. Europe: Multiple Sclerosis Therapeutics Market, by Country, 2019 & 2027 (%)
Figure 21. Germany: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 22. UK: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 23. France: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 24. Spain: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 25. Italy: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 26. Rest of Europe: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)
Figure 27. Impact of COVID-19 Pandemic in European Country Markets
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Horizon Therapeutics plc
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
Note: Product cover images may vary from those shown
Adroll
adroll